Last reviewed · How we verify
Solu-medrol 125 mg
At a glance
| Generic name | Solu-medrol 125 mg |
|---|---|
| Sponsor | Herlev Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial (PHASE3)
- Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer (PHASE1)
- MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction) (PHASE3)
- Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement (PHASE2)
- Treg Modulation With CD28 and IL-6 Receptor Antagonists (PHASE1, PHASE2)
- Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids (PHASE1)
- Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen (PHASE2)
- PreOperative Steroid in Abdominal Wall Reconstruction: A Double-blinded Randomized Clinical Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Solu-medrol 125 mg CI brief — competitive landscape report
- Solu-medrol 125 mg updates RSS · CI watch RSS
- Herlev Hospital portfolio CI